Citigroup Inc Corcept Therapeutics Inc Put Options Transaction History

Citigroup Inc

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 12, 2024	BUY	$29.51 - $46.26 $879,398 - $1.38 Million	29,800 New	29,800 $1.38 Million
Q4 2023 Feb 09, 2024	SELL	$24.82 - $32.88 $201,042 - $266,328	-8,100 Reduced 27.0%	21,900 $711,000
Q3 2023 Nov 09, 2023	SELL	$21.97 - $33.8 $448,188 - $689,520	-20,400 Reduced 40.48%	30,000 $817,000
Q2 2023 Aug 10, 2023	BUY	$21.44 - $25.15 $437,376 - $513,060	20,400 Added 68.0%	50,400 $1.12 Million
Q1 2023 May 11, 2023	BUY	$19.2 - $24.47 $576,000 - $734,100	30,000 New	30,000 $649,000
Q3 2022 Nov 10, 2022	BUY	$24.7 - $29.12 $494,000 - $582,400	20,000 Added 133.33%	35,000 $897,000
Q2 2022 Aug 10, 2022	BUY	$17.33 - $25.3 $259,949 - $379,500	15,000 New	15,000 $357,000

355

86.2M

1.12M

667K

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $7.17B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.